| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,270,000 |
| Market
Cap: |
273.14(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.29 - $35.72 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.1 |
| Insider 6 Months : 8.1 |
| Insider 3/6 Months : 16.7 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Revance Therapeutics is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. Co.'s segments are: Product, which refers to the business that includes the research, development and commercialization of its product candidates and the RHA® Collection of dermal fillers; and Service, which refers to the business that includes the development and commercialization of the OPUL™ Relational Commerce Platform and HintMD platform.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
30,000 |
30,000 |
30,000 |
30,000 |
| Total Buy Value |
$209,400 |
$209,400 |
$209,400 |
$209,400 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
29,089 |
29,089 |
291,945 |
446,160 |
| Total Sell Value |
$143,717 |
$143,717 |
$7,898,916 |
$12,719,522 |
| Total People Sold |
4 |
4 |
5 |
5 |
| Total Sell Transactions |
4 |
4 |
17 |
27 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Waugh Jacob |
Chief Scientific Officer |
• – – |
2014-05-19 |
4 |
A |
$32.22 |
$805,500 |
D/D |
25,000 |
78,333 |
|
- |
|
| Browne L Daniel |
CEO and President |
• • – |
2014-05-19 |
4 |
A |
$32.22 |
$3,093,120 |
D/D |
96,000 |
166,626 |
|
- |
|
| Ruegg Curtis |
EVP R&D and Tech Operations |
• – – |
2014-05-19 |
4 |
A |
$32.22 |
$338,310 |
D/D |
10,500 |
14,106 |
|
- |
|
| Silvernail Lauren P |
CFO, Seretary & EVP Corp Dev. |
• – – |
2014-05-19 |
4 |
A |
$32.22 |
$451,080 |
D/D |
14,000 |
14,000 |
|
- |
|
| Eastman Ronald W |
Director |
– • • |
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
407,289 |
117,458 |
|
- |
|
| Eastman Ronald W |
Director |
– • • |
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,727,673 |
105,898 |
|
- |
|
| Glasheen James Walter |
Director |
– • – |
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
52,236 |
709,162 |
|
- |
|
| Glasheen James Walter |
Director |
– • – |
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
673,778 |
657,075 |
|
- |
|
| Essex Woodlands Health Ventures Fund Viii-B Lp |
10% Owner |
– – • |
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
407,289 |
117,458 |
|
- |
|
| Essex Woodlands Health Ventures Fund Viii-B Lp |
10% Owner |
– – • |
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
3,727,673 |
105,898 |
|
- |
|
| Gardner Phyllis |
Director |
– • – |
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
12,839 |
457,085 |
|
- |
|
| Gardner Phyllis |
Director |
– • – |
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
444,246 |
444,246 |
|
- |
|
| Browne L Daniel |
CEO and President |
• • – |
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
17,702 |
71,035 |
|
- |
|
| Wooten Ronald J |
Director |
– • • |
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
398,717 |
3,096,650 |
|
- |
|
| Wooten Ronald J |
Director |
– • • |
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
2,697,933 |
2,697,933 |
|
- |
|
| Tunnicliffe Jonathan |
Director |
– • • |
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
398,717 |
3,096,650 |
|
- |
|
| Tunnicliffe Jonathan |
Director |
– • • |
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
2,697,933 |
2,697,933 |
|
- |
|
| Nq Hcif Gp, Ltd. |
10% Owner |
– – • |
2014-02-11 |
4 |
OE |
$0.00 |
$0 |
I/I |
398,717 |
3,096,650 |
|
- |
|
| Nq Hcif Gp, Ltd. |
10% Owner |
– – • |
2014-02-11 |
4 |
A |
$0.00 |
$0 |
I/I |
2,697,933 |
2,697,933 |
|
- |
|
| Ruegg Curtis |
EVP R&D and Tech OperationsOff |
• – – |
2014-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,606 |
|
- |
|
| Waugh Jacob |
Chief Scientific OfficerOffice |
• – – |
2014-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
53,333 |
|
- |
|
| Browne L Daniel |
CEO and PresidentOfficer |
• • – |
2014-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
53,333 |
|
- |
|
422 Records found
|
|
Page 17 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.97 (22.61%) 
